Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock, $0.001 par value · CUSIP: 05338F306
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Nantahala Capital Management, LLC
Shares: 900,000.00 · Class: 8.43%
- Wilmot B. Harkey
Shares: 900,000.00 · Class: 8.43%
- Daniel Mack
Shares: 900,000.00 · Class: 8.43%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-049515
- Form type
- SCHEDULE 13G
- Filer
- Avalo Therapeutics, Inc.
- CIK
- CIK 1534120
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership